Clinical Trial Update: VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pre-emptive azacitidine and donor lymphocyte infusions after allogeneic stem cell transplantation for high-risk acute myeloid leukemia …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Donor Lymphocyte Infusion
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Nantes University Hospital | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED